Abstract
In premature infants patent ductus arteriosus (PDA) is associated with the development of chronic pulmonary complications such as bronchopulmonary dysplasia. The precise pathogenesis of these complications is unknown.
We followed 13 infants (GA 2612 weels, b.w. 903±290 g, mean±SD) with PDA treated by indomethacin during the first week of Mo. As matched controls served 13 infants without PDA (GA 2711 weeks, b.w. 1041±430 g). Tracheal aspiratus were analyzed for myeloperoxidase (MPO) as an indicator of granulocyte activation. In patients with PDA before indomethacin treatment, treated MPO was 14.2±2.0 compared with 5.1±3.6 in controls (p<0.01). After Indomethacin treatment in PDA patients MPO decreased to 4.6±5.6 (p<0.001), whereas in untreated controls in remained unchanged 5.4±4.1 (N.S.).
Increased granulocyte activation in the lungs may contribute to the development of pulmonary complications in preterm infants with PDA.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuivalaipen, E., Venge, P. & Raizio, K. INCREASED PULMONARY GRANULOCYTE ACTIVATION IN PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS. Pediatr Res 35, 280 (1994). https://doi.org/10.1203/00006450-199402000-00153
Issue Date:
DOI: https://doi.org/10.1203/00006450-199402000-00153